tM2-PK在结直肠癌的应用价值临床研究
|
摘要
目的研究肿瘤型丙酮酸激酶(tM2-PK)在结直肠癌患者表达情况及其与结直肠癌临床病理特征的关系。方法以49例结直肠癌患者为研究对象,免疫组化检测癌组织以及癌旁组织tM2-PK表达情况,并研究癌组织tM2-PK与患者血清tM2-PK水平相关性,分析tM2-PK与结直肠癌患者病理特征关系。结果 49例结直肠癌患者癌组织与癌旁组织tM2-PK阳性率分别为81.6%、42.9%,两者存在统计学差异(P<0.05);结直肠癌组织最大Φ≥5cm结直肠癌tM2-PK阳性率高于最大Φ<5cm结直肠癌,在TNM分期中Ⅲ+Ⅳ期tM2-PK阳性率高于Ⅰ+Ⅱ期,不同Duck分期上C+D期tM2-PK阳性率高于A+B期;在不同年龄、性别以及不同分化程度上tM2-PK阳性率无统计学差异(P>0.05);40例结直肠癌患者癌组织tM2-PK阳性患者,平均评分7.53±1.94,其tM2-PK血清浓度26.59±10.24,两者呈正相关,r=0.876,P=0.001 5,有统计学意义(P<0.05)。结论 tM2-PK在结直肠癌的早期诊断,病情评估以及预后判断上有广阔前景。
Objective To study the tumor pyruvate kinase(tM2-PK)expression and its relationship with clinicopathological characteristics of colorectal cancer in patients with colorectal cancer.Methods 49 cases of colorectal cancer patients for the study,next to the immunohistochemistry cancer tissue and cancer tissue tM2-PK expression and cancer research organizations tM2-PK and serum tM2-PK levels in patients with correlation analysis tM2-PK colorectal cancer patients with pathological relationship.Results 49 cases of tissue tM2-PK positive rate of colorectal cancer in patients with cancer and adjacent tissues respectively 81.6%,42.9%,there was significant difference(P<0.05)between the two;colorectal cancer and colorectal largestΦ≥5cm cancer tM2-PK was higher than the maximum Φ<5cm of colorectal cancer in TNM stagingⅢ+Ⅳstage tM2-PK positive rate inⅠ+Ⅱstage,different stages Duck on C+D positive rate of tM2-PK higher than that of a+ B;no significant difference(P>0.05)at different ages,gender,and different degrees of differentiation on tM2-PK positive rate;40cases of colorectal cancer cancer tissues tM2-PK-positive patients,with an average score 7.53±1.94,serum concentrations tM2-PK 26.59±10.24,apositive correlation,r=0.876,P=0.0015,statistically significant(P<0.05).Conclusion tM2-PK in the early diagnosis of colorectal cancer,as well as assess the prognosis of the disease and has good prospects.
Objective To study the tumor pyruvate kinase(tM2-PK)expression and its relationship with clinicopathological characteristics of colorectal cancer in patients with colorectal cancer.Methods 49 cases of colorectal cancer patients for the study,next to the immunohistochemistry cancer tissue and cancer tissue tM2-PK expression and cancer research organizations tM2-PK and serum tM2-PK levels in patients with correlation analysis tM2-PK colorectal cancer patients with pathological relationship.Results 49 cases of tissue tM2-PK positive rate of colorectal cancer in patients with cancer and adjacent tissues respectively 81.6%,42.9%,there was significant difference(P<0.05)between the two;colorectal cancer and colorectal largestΦ≥5cm cancer tM2-PK was higher than the maximum Φ<5cm of colorectal cancer in TNM stagingⅢ+Ⅳstage tM2-PK positive rate inⅠ+Ⅱstage,different stages Duck on C+D positive rate of tM2-PK higher than that of a+ B;no significant difference(P>0.05)at different ages,gender,and different degrees of differentiation on tM2-PK positive rate;40cases of colorectal cancer cancer tissues tM2-PK-positive patients,with an average score 7.53±1.94,serum concentrations tM2-PK 26.59±10.24,apositive correlation,r=0.876,P=0.0015,statistically significant(P<0.05).Conclusion tM2-PK in the early diagnosis of colorectal cancer,as well as assess the prognosis of the disease and has good prospects.
引文
[1]李勇,王俊江,林锋,等.联合检测肿瘤M2-PK与CEA和FOBT对结直肠癌早期发现的意义[J].华南国防医学杂志,2011,25(6):479.
[2]卢仁泉,郭林,许晓峰.胃肠道恶性肿瘤患者血浆肿瘤型M2-丙酮酸激酶的测定及其临床价值[J].检验医学,2008,23(4):370.
[3]谭莉,王琳,巴亚斯古楞,等.一种新的肿瘤标志物TU-M2-PK的研究进展[J].中外医学研究,2011,9(34):159.
[4]方伟达,梁文勇,余其昌.肿瘤型M2丙酮酸激酶在乳腺癌中的表达的意义及其临床应用价值[J].中国医药导报,2010,7(35):22.
[5]叶维洁,金冶宁.肿瘤型丙酮酸激酶在在结直肠癌血浆中的测定及其临床应用价值[J].现代肿瘤医学,2010,18(03):511.
[6]孙倩.M2型丙酮酸激酶(PKM2)在肿瘤代谢和发生中的作用[J].基础医学与临床,2012,32(5):462.
[7]梁道源,姚桂琴.肿瘤型丙酮酸激酶与消化系统肿瘤的研究[J].医学综述,2007,13(13):984.
[8]MGV Heiden,JW Locasale,KD Swanson,et al.Evidence for an alternative glycolytic pathway in rapidly proliferating cells[J].Science,2010,329(5998):1492.
[9]W Luo,H Hu,R Chang,et al.Pyruvate kinase M2is a PHD3-stimulated coactivator for hypoxia-inducible factor 1[J].Cell,2011,145(5):732.
[10]S Mazurek.Pyruvate kinase type M2:a key regulator of the metabolic budget system in tumor cells.[J].International Journal of Biochemistry&Cell B,2011,43(7):969.
[11]Schneider J,Bitterlich N,Schulze G.Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK[J].Anticancer Res,2005,25(3A):1507.
[12]W Thian-Sze,L Xiao-Bing,CWH Ambrose,et al.Identification of pyruvate kinase type M2as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling[J].International Journal of Cancer Journal Intern,2008,123(2):251.
[13]詹成,时雨,王群.丙酮酸激酶M2型应用于肿瘤诊断与治疗的研究进展[J].中华肿瘤防治杂志,2013,29(13):1043.
[2]卢仁泉,郭林,许晓峰.胃肠道恶性肿瘤患者血浆肿瘤型M2-丙酮酸激酶的测定及其临床价值[J].检验医学,2008,23(4):370.
[3]谭莉,王琳,巴亚斯古楞,等.一种新的肿瘤标志物TU-M2-PK的研究进展[J].中外医学研究,2011,9(34):159.
[4]方伟达,梁文勇,余其昌.肿瘤型M2丙酮酸激酶在乳腺癌中的表达的意义及其临床应用价值[J].中国医药导报,2010,7(35):22.
[5]叶维洁,金冶宁.肿瘤型丙酮酸激酶在在结直肠癌血浆中的测定及其临床应用价值[J].现代肿瘤医学,2010,18(03):511.
[6]孙倩.M2型丙酮酸激酶(PKM2)在肿瘤代谢和发生中的作用[J].基础医学与临床,2012,32(5):462.
[7]梁道源,姚桂琴.肿瘤型丙酮酸激酶与消化系统肿瘤的研究[J].医学综述,2007,13(13):984.
[8]MGV Heiden,JW Locasale,KD Swanson,et al.Evidence for an alternative glycolytic pathway in rapidly proliferating cells[J].Science,2010,329(5998):1492.
[9]W Luo,H Hu,R Chang,et al.Pyruvate kinase M2is a PHD3-stimulated coactivator for hypoxia-inducible factor 1[J].Cell,2011,145(5):732.
[10]S Mazurek.Pyruvate kinase type M2:a key regulator of the metabolic budget system in tumor cells.[J].International Journal of Biochemistry&Cell B,2011,43(7):969.
[11]Schneider J,Bitterlich N,Schulze G.Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK[J].Anticancer Res,2005,25(3A):1507.
[12]W Thian-Sze,L Xiao-Bing,CWH Ambrose,et al.Identification of pyruvate kinase type M2as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling[J].International Journal of Cancer Journal Intern,2008,123(2):251.
[13]詹成,时雨,王群.丙酮酸激酶M2型应用于肿瘤诊断与治疗的研究进展[J].中华肿瘤防治杂志,2013,29(13):1043.